Study #2020-0412
Niraparib (PARP inhibitor) plus dostarlimab (anti-PD1) for small cell lung cancer (SCLC) and other high-grade neuroendocrine carcinomas (NEC)
MD Anderson Study Status
Not Accepting
Treatment Agent
Dostarlimab, Niraparib
Description
This phase II trial studies the effect of niraparib and dostarlimab in treating small cell lung cancer and other high-grade neuroendocrine carcinomas. Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Immunotherapy with monoclonal antibodies, such as dostarlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving niraparib and dostarlimab may help to control the diseases.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lung Small Cell Carcinoma, Neuroendocrine Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
Study phase:
Phase II
Physician name:
Carl Gay
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-855-893-4229
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.